Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus

Liang, KL; He, J; Wei, YB; Zeng, QX; Gong, DC; Qin, JH; Ding, HH; Chen, Z; Zhou, P; Niu, P; Chen, Q; Ding, CG; Lu, LJ; Chen, XX; Li, ZG; Shen, N; Yu, D; Deng, J

Shen, N; Yu, D; Deng, J (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, China Australia Ctr Personalized Immunol, Sch Med SJTUSM, 160 Pujian Rd, Shanghai 200120, Peoples R China.; Li, ZG (corresponding author), Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, 11 Xizhimen South St, Beijing 100044, Peoples R China.

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021; 10 (6):

Abstract

Objectives. Low-dose interleukin-2 (IL-2) has shown promising clinical benefits in the treatment of systemic lupus erythematosus (SLE), but how this t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索